20 results about "Beta-Adrenergic Agonist" patented technology

The invention relates to a synthesis method of an intermediate for preparing a THR-beta agonist, and belongs to the technical field of medicine synthesis. The synthesis method of the intermediate for preparing the THR-beta agonist is realized by utilizing a substitution reaction of 1H-pyrazolo [4, 3-b] pyridine and 2, 6-dichloro-p-nitrofluorobenzene and a Katada reaction, has the advantages of easiness in large-scale production, controllable quality, controllable cost and the like, and compared with an existing preparation method, the yield of the preparation method disclosed by the invention is greatly improved, and the synthesis method is suitable for industrial production. The raw materials are cheap, easy to obtain, simple and efficient, and have great industrialization prospects.

The present disclosure is directed to a method of monitoring treatment of metabolic dysfunction-associated steatohepatitis (MASH) in a patient by initiating a treatment by administering Compound 1: (Compound 1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient, determining percentage increase in the level of SHBG from baseline, and continuing administration of Compound 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient if the percentage increase in the level of SHBG is at least 50% from baseline.

The invention relates to the field of biological medicine, in particular to an aryloxy indole formic acid compound as well as a preparation method and application thereof. The general formula (I) of the aryloxy indole carboxylic acid compound is shown in the specification, wherein R1 is a Cl atom or a Br atom; r2 and R3 are two methylene groups connected to the same oxygen atom, or R2 is any one of a methyl group, a methoxy group, an isopropyl group, a methylthio group and a hydrogen atom, and R3 is any one of a halogen atom, a methyl group, a methoxy group, an isopropyl group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a cyclopropyl methoxy group, a benzyl group, a benzyloxy group and a hydrogen atom. As a thyroid hormone receptor agonist, the aryloxy indole formic acid compound has good THRbeta selectivity and THRbeta agonist activity, has the advantages of low toxicity and good biological safety, and has high practical value.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. In certain embodiments of the methods disclosed herein, the methods include administering to the subject a compound as disclosed herein and a peripherally acting P-blocker (PABRA).

Disclosed herein are pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more surfactants, and methods of treating disease by administering or contacting a subject with one or more of the above pharmaceutical compositions.

The invention discloses a cell model for simulating acute pressure alopecia as well as a construction method and application thereof, the construction method comprises the following steps: A, culturing primary hair papilla cells obtained by separation, and performing passage; and B, stimulating the passage cells for 24-72 hours by using an adrenergic receptor beta agonist, and then measuring the cell activity and the expression quantity of an alopecia-related gene DKK1, thereby obtaining the cell model for simulating acute stress alopecia. The adrenergic receptor beta agonist is used for inducing the hair papilla cells, and the obtained hair papilla cell model can simulate the physiological characteristics of the hair papilla cells of people under acute pressure; based on the model, a substance used for preventing and / or relieving acute pressure alopecia or used for evaluating the anti-alopecia effect of a to-be-detected substance on acute pressure alopecia can be further screened out, and a new solution is provided for developing products or methods for preventing and / or relieving acute pressure alopecia and promoting hair regeneration under pressure.

The invention discloses a multi-organ regulation and control combined nano preparation and application thereof, and belongs to the technical field of medicines. The combined nano preparation consists of a nano preparation A and a nano preparation B, the nano preparation A is a parenchymal hepatic cell regulation and control nano delivery system and is prepared from phospholipid, cholesterol, PEGylated phospholipid, DSPE-PEG-Glactase and a THR-beta agonist; and the nano preparation B is an adipose cell regulation and control nano delivery system and is prepared from phospholipid, cholesterol, PEGylated phospholipid, DSPE-PEG-CKGGRAKDC and a PPAR gamma agonist. According to the invention, malignant crosstalk formed by liver-adipose tissue axes is utilized for the first time, and a strategy for treating fatty hepatitis and hepatic fibrosis related to metabolic dysfunction by cooperatively regulating lipid metabolism balance between two organs of liver and fat by using two types of liposomes is innovatively provided; the invention provides a new strategy and way for treating metabolic liver diseases.

A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRbeta) agonist, and methods comprising administering such combinations to a subject in need thereof.

The present invention discloses compounds of formula (I), as thyroid hormone receptor β subtype agonists or modulators for use in methods of treatment of obesity, hyperlipidemia, hypercholesterolemia, diabetes mellitus, nonalcoholic steatohepatitis (NASH), hepatic steatosis, arteriosclerosis, cardiovascular disease, hypothyroidism, overweight, fibrosis, thyroid cancer and alopecia, and in chronic weight management or weight management.

The invention relates to application of a PPAR full agonist combined with a THR-beta agonist in preparation of drugs for preventing and / or improving and / or treating metabolism-related diseases. The combination of the PPAR full agonist and the THR-beta agonist can comprehensively and better reduce the weight of a diabetic mouse, control blood sugar, regulate blood fat, reduce liver and kidney injury and liver lipid accumulation, and reduce liver NAS score and fibrosis, which indicates that the combination of the PPAR full agonist and the THR-beta agonist has potential to improve and treat metabolism-related diseases.

The application discloses a triazine dione compound as a thyroid hormone receptor agonist, and synthesis and application thereof, and belongs to the field of medicines. The application provides a triazine dione compound as shown in a structure of formula (I) or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate compound, a crystal form, a stereoisomer or an isotopic variant thereof. The compound of the application is a THR-beta agonist, and can be used for treating and / or preventing diseases regulated by thyroid hormone analogues.

The present invention relates to a pharmaceutical composition for preventing or treating atherosclerosis and, more specifically, to a pharmaceutical composition for preventing or treating atherosclerosis that comprises a beta agonist or a pharmaceutically acceptable salt thereof, thereby promoting apoptotic cell removal and inhibiting plaque formation.

To provide modified IL2 polypeptides and fusion proteins thereof. Methods of modulating immune responses by administering modified IL2 polypeptides or fusion proteins thereof are also provided.SOLUTION: Disclosed is a modified interleukin 2 (IL2) polypeptide comprising a modified IL2R receptor beta (IL2 beta) binding region 2 comprising X1 - X2 - X3 - D - X4 - X5 - X6 - X7 - X8 - X9 - X10 - X11 - X12 - X13 (SEQ ID NO: 1). Wherein X1, X3, X6, X8, X12, and X13 each comprise any residues; X2, X4, and X10 are uncharged residues; X5, X7, X9, and X11 each comprise uncharged apolar residues. Modified IL2 polypeptides and fusion proteins thereof exhibit increased binding to IL2R β, decreased binding to IL2R α, or both.SELECTED DRAWING: Figure 1A

The present disclosure relates generally to various forms and compositions useful as beta adrenergic agonists and the use of the various forms and compositions in the treatment of diseases associated with adrenergic receptors. In one aspect, the present disclosure provides: crystalline solid forms of Compound 1 selected from Form A and Form B; and salt forms of Compound 1.